Cabazitaxel (Jevtana, RPR-116258, Taxoid XRP6258, TXD-258, XRP-6258, CAS 183133-96-2), >99%

LC Laboratories' Product Number C-2581 - Cabazitaxel (Jevtana, RPR-116258, Taxoid XRP6258, TXD-258, XRP-6258, CAS 183133-96-2), >99% - for research use only. Cabazitaxel, also known as XRP-6258, is a second-generation semi-synthetic derivative of paclitaxel, a natural taxoid microtubule inhibitor. In preclinical studies, cabazitaxel was shown to have antitumor activity in a variety of docetaxel-refractory in vitro and in vivo models. 755 participants with metastatic castration-resistant prostate cancer who had received previous hormone therapy were treated with prednisone daily, and were randomly allocated to treatment groups (377 mitoxantrone and 378 cabazitaxel). Median survival was 15.1 months in the cabazitaxel group and 12.7 months in the mitoxantrone group. Median progression-free survival was 2.8 months in the cabazitaxel group and 1.4 months in the mitoxantrone group. When compared with docetaxel and paclitaxel, cabazitaxel was reported to have poor affinity for the ATP-dependent drug efflux pump, P-glycoprotein 1 (P-gp), and greater penetration of the blood-brain barrier. Brain uptake of cabazitaxel was increased when concentrations exceeded 11 µM and the saturation was found to be at 13 µM, suggesting the role of a critical transporter (that is, P-gp) in transporting cabazitaxel across the blood-brain barrier upon a certain threshold. Cabazitaxel is the active ingredient in the drug product sold under the trade name Jevtana®. This drug is currently approved in at least one country for use in patients with hormone-refractory metastatic prostate cancer. NOTE: THE CABAZITAXEL RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT JEVTANA®, AND IS NOT FOR HUMAN USE.

• Supplier: LC Laboratories
• Product #: C-2581
• Sku #: C-2581_2g